摘要
目的探究重度以上慢性阻塞性肺疾病(慢阻肺)行噻托溴铵联合舒利迭治疗的临床效果和安全性。方法方便择取2018年7月—2019年6月期间该院收治的72例重度以上慢阻肺患者,进行随机分组,其中观察组(36例)、对照组(36例)。对照组患者开展舒利迭治疗,观察组患者开展噻托溴铵联合舒利迭治疗,对两组患者临床疗效、肺功能指标、英国医学研究委员会改良版呼吸困难评分(MMRC)及不良反应发生率进行比较。结果观察组患者临床治疗总有效率91.67%高于对照组72.22%,经比较差异有统计学意义(χ^2=4.600,P<0.05);观察组患者肺功能指标FEV1(1.12±0.06)L、FVC(1.86±0.11)L、FEV1/FVC(0.61±0.05)高于对照组[(0.85±0.04)L、(1.52±0.13)L、(0.42±0.03)],MMRC评分(1.48±0.15)分低于对照组(1.84±0.12)分,经比较差异有统计学意义(t=22.465、11.979、19.551、11.245,P<0.05);观察组不良反应发生率5.56%低于对照组的13.89%,经比较差异无统计学意义(χ^2=0.633,P>0.05)。结论针对重度以上慢阻肺患者开展噻托溴铵联合舒利迭治疗的效果优良,不良反应风险极少,对患者肺功能具有良好的改善效果,因此该种治疗方法可用于临床推广。
Objective To explore the clinical effect and safety of tiotropium bromide combined with seretide for severe chronic obstructive pulmonary disease(COPD).Methods From July 2018 to June 2019,72 patients with severe chronic obstructive pulmonary obstructive pulmonary disease in the hospital were selected and randomly divided into observation group(36 cases)and control group(36 cases).Patients in the control group were convenient treated with seretide,and patients in the observation group were treated with tiotropium bromide combined with seretide.The clinical efficacy,pulmonary function indexes,British Medical Research Council’s modified version of dyspnea score(MMRC)and adverse reactions performed on the two groups of patients were compared.Results The total effective rate of clinical treatment of patients in the observation group was 91.67%higher than 72.22%in the control group.The difference was statistically significant after comparison(χ^2=4.600,P<0.05);the pulmonary function indexes FEV1(1.12±0.06)L,FVC(1.86±0.11)L,FEV1/FVC(0.61±0.05)were higher than the control group by[(0.85±0.04)L,(1.52±0.13)L,(0.42±0.03)],and the MMRC score(1.48±0.15)points was lower than the control group by(1.84±0.12)points.The difference was statistically significant(t=22.465,11.979,19.551,11.245,P<0.05);the incidence of adverse reactions in the observation group 5.56%was lower than that of the control group,13.89%,the difference was not statistically significant(χ^2=0.633,P>0.05).Conclusion The treatment of tiotropium bromide combined with seretide for patients with severe chronic obstructive pulmonary disease is effective,with minimal risk of adverse reactions,and has a good effect on improving the lung function of patients.Therefore,this treatment method can be used for clinical promotion.
作者
庞珂
乔伟
PANG Ke;QIAO Wei(Department of Respiratory Medicine,Shandong Rongjun General Hospital,Jinan,Shandong Province,250013 China;Department of Cardiovascular Medicine,Shandong Rongjun General Hospital,Jinan,Shandong Province,250013 China)
出处
《中外医疗》
2020年第26期84-86,共3页
China & Foreign Medical Treatment
关键词
重度疾病
慢阻肺
噻托溴铵
舒利迭
肺功能
Severe disease
Chronic obstructive pulmonary disease
Tiotropium bromide
Seretide
Lung function
